Greater Response to Placebo in Children Than in Adults: A Systematic Review and Meta-Analysis in Drug-Resistant Partial Epilepsy

English version České info

Background:
Despite guidelines establishing the need to perform comprehensive paediatric drug development programs, pivotal trials in children with epilepsy have been completed mostly in Phase IV as a postapproval replication of adult data. However, it has been shown that the treatment response in children can differ from that in adults. It has not been investigated whether differences in drug effect between adults and children might occur in the treatment of drug-resistant partial epilepsy, although such differences may have a substantial impact on the design and results of paediatric randomised controlled trials (RCTs).

Methods and Findings:
Three electronic databases were searched for RCTs investigating any antiepileptic drug (AED) in the add-on treatment of drug-resistant partial epilepsy in both children and adults. The treatment effect was compared between the two age groups using the ratio of the relative risk (RR) of the 50% responder rate between active AEDs treatment and placebo groups, as well as meta-regression. Differences in the response to placebo and to active treatment were searched using logistic regression. A comparable approach was used for analysing secondary endpoints, including seizure-free rate, total and adverse events-related withdrawal rates, and withdrawal rate for seizure aggravation. Five AEDs were evaluated in both adults and children with drug-resistant partial epilepsy in 32 RCTs. The treatment effect was significantly lower in children than in adults (RR ratio: 0.67 [95% confidence interval (CI) 0.51–0.89]; p = 0.02 by meta-regression). This difference was related to an age-dependent variation in the response to placebo, with a higher rate in children than in adults (19% versus 9.9%, p < 0.001), whereas no significant difference was observed in the response to active treatment (37.2% versus 30.4%, p = 0.364). The relative risk of the total withdrawal rate was also significantly lower in children than in adults (RR ratio: 0.65 [95% CI 0.43–0.98], p = 0.004 by metaregression), due to higher withdrawal rate for seizure aggravation in children (5.6%) than in adults (0.7%) receiving placebo (p < 0.001). Finally, there was no significant difference in the seizure-free rate between adult and paediatric studies.

Conclusions:
Children with drug-resistant partial epilepsy receiving placebo in double-blind RCTs demonstrated significantly greater 50% responder rate than adults, probably reflecting increased placebo and regression to the mean effects. Paediatric clinical trial designs should account for these age-dependent variations of the response to placebo to reduce the risk of an underestimated sample size that could result in falsely negative trials.

Vyšlo v časopise: Greater Response to Placebo in Children Than in Adults: A Systematic Review and Meta-Analysis in Drug-Resistant Partial Epilepsy. PLoS Med 5(8): e166. doi:10.1371/journal.pmed.0050166
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.0050166

Souhrn

Zdroje

1. GuerriniR

2006

Epilepsy in children.

Lancet

367

499

524

2. GarofaloE

2006

Obtaining pediatric indications for new anti-epileptic drugs: how and when.

Epilepsy Res

3. SchmidtB

2007

Clinical development of antiepileptic drugs in adults.

Neurotherapeutics

4. CaldwellPHMurphySBButowPNCraigJC

2004

Clinical trials in children.

Lancet

364

803

811

5. PellockJM

1998

Pediatric trials: practical issues. Special populations and trial design.

Adv Neurol

167

171

6. SteinbrookR

2002

Testing medications in children.

N Engl J Med

347

1462

1470

7. PeruccaE

2006

Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age.

Clin Pharmacokinet

351

363

8. ShinnarSPellockJM

2005

The trials and tribulations of pediatric drug trials.

Neurology

1348

1349

9. SandlerA

2005

Placebo effects in developmental disabilities: implications for research and practice.

Ment Retard Dev Disabil Res Rev

164

170

10. FernandesRFerreiraJJSampaioC

2008

The placebo response in studies of acute migraine.

J Pediatr

152

527

533.e.l

11. LewisDWWinnerPWasiewskiW

2005

The placebo responder rate in children and adolescents.

Headache

232

239

12. RothnerADWasiewskiWWinnerPLewisDStankowskiJ

2006

Zolmitriptan oral tablet in migraine treatment: high placebo responses in adolescents.

Headache

101

109

13. [No authors listed]

1993

Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome). The Felbamate Study Group in Lennox-Gastaut Syndrome.

N Engl J Med

328

14. BeranRGBerkovicSFDunaganFMVajdaFJDantaG

1998

Double-blind, placebo-controlled, crossover study of lamotrigine in treatment-resistant generalised epilepsy.

Epilepsia

1329

1333

15. BerkovicSFKnowltonRCLeroyRFSchiemannJFalterU

2007

Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy.

Neurology

1751

1760

16. BitonVMontourisGDRitterFRivielloJJReifeR

1999

A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Topiramate YTC Study Group.

Neurology

1330

1337

17. BitonVSackellaresJCVuongAHammerAEBarrettPS

2005

Double-blind, placebo-controlled study of lamotrigine in primary generalized tonic-clonic seizures.

Neurology

1737

1743

18. ChadwickDLeidermanDBSauermannWAlexanderJGarofaloE

1996

Gabapentin in generalized seizures.

Epilepsy Res

191

197

19. GlauserTKlugerGSachdeoRKraussGPerdomoC

2008

Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome.

Neurology

1950

1958

20. MotteJTrevathanEArvidssonJFBarreraMNMullensEL

1997

Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut Study Group.

N Engl J Med

337

1807

1812

21. SachdeoRCGlauserTARitterFReifeRLimP

1999

A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Topiramate YL Study Group.

Neurology

1882

1887

22. [No authors listed]

1989

Proposal for revised classification of epilepsies and epileptic syndromes. Commission on Classification and Terminology of the International League Against Epilepsy.

Epilepsia

389

399

23. FrenchJAKannerAMBautistaJAbou-KhalilBBrowneT

2004

Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society.

Neurology

1261

1273

24. GumnitRJWalczakTS

2001

Guidelines for essential services, personnel, and facilities in specialized epilepsy centers in the United States.

Epilepsia

804

814

25. PerrucaE

1998

Pharmacoresistance in epilepsy: how should it be defined.

CNS Drugs

171

179

26. RegestaGTanganelliP

1999

Clinical aspects and biological bases of drug-resistant epilepsies.

Epilepsy Res

109

122

27. European Medicines Agency

2001

International Conference on Harmonisation.

ICH topic E11 clinical investigation of medicinal products in the paediatric population

Available: http://www.emea.eu/pdfs/human/ich/271199EN.pdf. Accessed 07 July 2008.

28. JadadARMooreRACarrollDJenkinsonCReynoldsDJ

1996

Assessing the quality of reports of randomized clinical trials: is blinding necessary.

Control Clin Trials

29. GazzolaDMBalcerLJFrenchJA

2007

Seizure-free outcome in randomized add-on trials of the new antiepileptic drugs.

Epilepsia

1303

1307

30. HigginsJPThompsonSG

2002

Quantifying heterogeneity in a meta-analysis.

Stat Med

1539

1558

31. CucheratM

2000

EasyMA Sofware Version 2000

Available: http://www.spc.univ-lyon1.fr/easyma.net/. Accessed 07 July 08.

32. CucheratMBoisselJPLeizoroviczAHaughMC

1997

EasyMA: a program for the meta-analysis of clinical trials.

Comput Methods Programs Biomed

187

190

33. RosenfeldWAbou-KhalilBReifeRHegadusRPledgerG

1996

Placebo-controlled trial of topiramate as adjunctive therapy to carbamazepine or phenitoine for partial onset seizures.

Epilepsia

153

34. SchmidtDRiedRSRappP

1993

Add-on treatment with Lamotrigine for intractable partial epilepsy: a placebo-controlled, cross-over trial.

Epilepsia

35. JetteNJMarsonAGHuttonJL

2002

Topiramate add-on for drug-resistant partial epilepsy.

Cochrane Database Syst Rev CD001417

Available: http://www.cochrane.org/reviews/en/ab001417.html. Accessed 07 July 08.

36. RamaratnamSMarsonAGBakerGA

2001

Lamotrigine add-on for drug-resistant partial epilepsy.

Cochrane Database Syst Rev CD001909

Available: http://www.cochrane.org/reviews/en/ab001909.html. Accessed 07 July 08.

37. DuchownyMPellockJMGrafWDBillardCGilmanJ

1999

A placebo-controlled trial of lamotrigine add-on therapy for partial seizures in children. Lamictal Pediatric Partial Seizure Study Group.

Neurology

1724

1731

38. Huedo-MedinaTBSanchez-MecaFMarin-MartinezFBotellaJ

2006

Assessing heterogenity in meta-analysi: Q statistic or I2 index.

Psychol Methods

193

206

39. IoannidisJPatsopoulosNEvangelouE

2007

Uncertainty in heterogeneity estimates in meta-analyses.

BMJ

335

914

916

40. HoppeCPoepelAElgerCE

2007

Epilepsy: accuracy of patient seizure counts.

Arch Neurol

1595

1599

41. KerlingFMuellerSPauliEStefanH

2006

When do patients forget their seizures? An electroclinical study.

Epilepsy Behav

281

285

42. CastilloSSchmidtDBWhiteS

2000

Oxcarbazepine add-on for drug-resistant partial epilepsy.

Cochrane Database Syst Rev CD002028

Available: http://www.cochrane.org/reviews/en/ab002028.html. Accessed 07 July 08.

43. ChadwickDWMarsonAG

2005

Zonisamide add-on for drug-resistant partial epilepsy.

Cochrane Database Syst Rev CD001416

Available: http://www.cochrane.org/reviews/en/ab001416.html. Accessed 07 July 08.

44. ChaisewikulRPriviteraMDHuttonJLMarsonAG

2001

Levetiracetam add-on for drug-resistant localization related (partial) epilepsy.

Cochrane Database Syst Rev CD001901

http://www.cochrane.org/reviews/en/ab001901.html. Accessed 07 July 08.

45. LeachJPMarsonAGHuttonJL

2002

Remacemide for drug-resistant localization related epilepsy.

Cochrane Database Syst Rev CD001900

Available: http://www.cochrane.org/reviews/en/ab001900.html. Accessed 07 July 08.

46. LozsadiDHemmingKMarsonA

2008

Pregabalin add-on for drug-resistant partial epilepsy.

Cochrane Database Syst Rev CD005612

Available: http://www.cochrane.org/reviews/en/ab005612.html. Accessed 07 July 08.

47. MarsonAGKadirZAHuttonJLChadwickDW

2000

Gabapentin add-on for drug-resistant partial epilepsy.

Cochrane Database Syst Rev CD001415

Available: http://www.cochrane.org/reviews/en/ab001415.html. Accessed 07 July 08.

48. PereiraJMarsonAGHuttonJL

2002

Tiagabine add-on for drug-resistant partial epilepsy.

Cochrane Database Syst Rev CD001908

Available: http://www.cochrane.org/reviews/en/ab001908.html. Accessed 07 July 08.

49. MarsonAGHuttonJLLeachJPCastilloSSchmidtD

2001

Levetiracetam, oxcarbazepine, remacemide and zonisamide for drug resistant localization-related epilepsy: a systematic review.

Epilepsy Res

259

270

50. MarsonAGKadirZAHuttonJLChadwickDW

1997

The new antiepileptic drugs: a systematic review of their efficacy and tolerability.

Epilepsia

859

880

51. OtoulCArrigoCvan RijckevorselKFrenchJA

2005

Meta-analysis and indirect comparisons of levetiracetam with other second-generation antiepileptic drugs in partial epilepsy.

Clin Neuropharmacol

52. [No authors listed]

2006

Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medical products for paediatric use

Official Journal of the European Union

Available: http://ec.europa.eu/enterprise/pharmaceuticals/eudralex/vol-1/reg_2006_1901/reg_2006_1901_en.pdf. Accessed 07 July 08.

53. National Institutes of Health

1998

NIH policy and guidelines on the inclusion of children as participants in research involving human subjects

Available: http://grants.nih.gov/grants/guide/notice-files/not98–024.html. Accessed 07 July 08.

54. AppletonRFichtnerKLaMoreauxLAlexanderJHalsallG

1999

Gabapentin as add-on therapy in children with refractory partial seizures: a 12-week, multicentre, double-blind, placebo-controlled study. Gabapentin Paediatric Study Group.

Epilepsia

1147

1154

55. EltermanRDGlauserTAWyllieEReifeRWuSC

1999

A double-blind, randomized trial of topiramate as adjunctive therapy for partial-onset seizures in children. Topiramate YP Study Group.

Neurology

1338

1344

56. AnhutHAshmanPFeuersteinTJSauermannWSaundersM

1994

Gabapentin (Neurontin) as add-on therapy in patients with partial seizures: a double-blind, placebo-controlled study. The International Gabapentin Study Group.

Epilepsia

795

801

57. TassinariCAMichelucciRChauvelPChodkiewiczJShorvonS

1996

Double-blind, placebo-controlled trial of topiramate (600 mg daily) for the treatment of refractory partial epilepsy.

Epilepsia

763

768

58. YamauchiTKanekoSYagiKSaseS

2006

Treatment of partial seizures with gabapentin: double-blind, placebo-controlled, parallel-group study.

Psychiatry Clin Neurosci

507

515

59. Pina-GarzaJEEspinozaRNordliDBennettDASpiritoS

2005

Oxcarbazepine adjunctive therapy in infants and young children with partial seizures.

Neurology

1370

1375

60. ChironCTonnelierSReyEBrunetMLTranA

2006

Stiripentol in childhood partial epilepsy: randomized placebo-controlled trial with enrichment and withdrawal design.

J Child Neurol

496

502

61. ChironCDulacOGramL

1996

Vigabatrin withdrawal randomized study in children.

Epilepsy Res

209

215

62. ChironCDulacOPonsG

2008

Antiepileptic drug development in children: considerations for a revisited strategy.

Drugs

63. Pina-GarzaJELevisohnPGucuyenerKMikatiMAWarnockCR

2007

Adjunctive lamotrigine for partial seizures in patients aged 1 to 24 months.

Neurology

64. [No authors listed]

1990

Gabapentin in partial epilepsy. UK Gabapentin Study Group.

Lancet

335

1114

1117

65. SiveniusJKalviainenRYlinenARiekkinenP

1991

Double-blind study of Gabapentin in the treatment of partial seizures.

Epilepsia

539

542

66. [No authors listed]

1993

Gabapentin as add-on therapy in refractory partial epilepsy: a double-blind, placebo-controlled, parallel-group study. The US Gabapentin Study Group No. 5.

Neurology

2292

2298

67. BinnieCDDebetsRMEngelsmanMMeijerJWMeinardiH

1989

Double-blind crossover trial of lamotrigine (Lamictal) as add-on therapy in intractable epilepsy.

Epilepsy Res

222

229

68. JawadSRichensAGoodwinGYuenWC

1989

Controlled trial of lamotrigine (Lamictal) for refractory partial seizures.

Epilepsia

356

363

69. LoiseauPYuenAWDucheBMenagerTArne-BesMC

1990

A randomised double-blind placebo-controlled crossover add-on trial of lamotrigine in patients with treatment-resistant partial seizures.

Epilepsy Res

136

145

70. MatsuoFBergenDFaughtEMessenheimerJADrenAT

1993

Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. U.S. Lamotrigine Protocol 0.5 Clinical Trial Group.

Neurology

2284

2291

71. SchapelGJBeranRGVajdaFJBerkovicSFMashfordML

1993

Double-blind, placebo controlled, crossover study of lamotrigine in treatment resistant partial seizures.

J Neurol Neurosurg Psychiatry

448

453

72. SmithDBakerGDaviesGDeweyMChadwickDW

1993

Outcomes of add-on treatment with lamotrigine in partial epilepsy.

Epilepsia

312

322

73. MessenheimerJRamsayREWillmoreLJLeroyRFZielinskiJJ

1994

Lamotrigine therapy for partial seizures: a multicenter, placebo-controlled, double-blind, cross-over trial.

Epilepsia

113

121

74. BoasJDamMFriisMLKristensenOPedersenB

1996

Controlled trial of lamotrigine (Lamictal) for treatment-resistant partial seizures.

Acta Neurol Scand

247

252

75. Ben-MenachemEFalterU

2000

Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group.

Epilepsia

1276

1283

76. CereghinoJJBitonVAbou-KhalilBDreifussFGauerLJ

2000

Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial.

Neurology

236

242

77. ShorvonSDLowenthalAJanzDBielenELoiseauP

2000

Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group.

Epilepsia

1179

1186

78. TsaiJJYenDJHsihMSChenSSHiersemenzelR

2006

Efficacy and safety of levetiracetam (up to 2000 mg/day) in Taiwanese patients with refractory partial seizures: a multicenter, randomized, double-blind, placebo-controlled study.

Epilepsia

79. GlauserTAAyalaREltermanRDMitchellWGVan OrmanCB

2006

Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures.

Neurology

1654

1660

80. BarcsGWalkerEBElgerCEScaramelliAStefanH

2000

Oxcarbazepine placebo-controlled, dose-ranging trial in refractory partial epilepsy.

Epilepsia

1597

1607

81. GlauserTANigroMSachdeoRPasterisLAWeinsteinS

2000

Adjunctive therapy with oxcarbazepine in children with partial seizures. The Oxcarbazepine Pediatric Study Group.

Neurology

2237

2244

82. Ben-MenachemEHenriksenODamMMikkelsenMSchmidtD

1996

Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures.

Epilepsia

539

543

83. FaughtEWilderBJRamsayREReifeRAKramerLD

1996

Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages. Topiramate YD Study Group.

Neurology

1684

1690

84. PriviteraMFinchamRPenryJReifeRKramerL

1996

Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1,000-mg daily dosages. Topiramate YE Study Group.

Neurology

1678

1683

85. ShariefMViteriCBen-MenachemEWeberMReifeR

1996

Double-blind, placebo-controlled study of topiramate in patients with refractory partial epilepsy.

Epilepsy Res

217

224

86. Korean

1999

Topiramate in medically intractable partial epilepsies: double-blind placebo-controlled randomized parallel group trial. Korean Topiramate Study Group.

Epilepsia

1767

1774

87. YenDJYuHYGuoYCChenCYiuCH

2000

A double-blind, placebo-controlled study of topiramate in adult patients with refractory partial epilepsy.

Epilepsia

1162

1166